Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Longevity |
| Evidence grade | Moderate |
| Also known as | Elamipretide, MTP-131 |
| Mechanism | Concentrates in the inner mitochondrial membrane where it binds cardiolipin, stabilising cristae architecture, improving electron-transport efficiency and reducing reactive oxygen species leakage. |
| Key benefits | Improved mitochondrial ATP output · Reduced oxidative stress markers · Fatigue improvement in mitochondrial disease trials |
| Side effects | Injection-site reactions are common and can be significant · Headache · Dizziness |
| Half-life | Roughly 2 hours |
| Administration | Daily subcutaneous injection |
| Dosing overview | Trial dosing around 40 mg daily; community protocols use less |
| Storage | Refrigerate; protect from light |
| Legal status | Investigational drug, not approved for general use. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.